NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.80
−1.18%Next report
Analyst consensus
- Next report date
- Feb 17, 2027
- EPS estimate
- -$0.41
- Revenue estimate
- $38.0M
Latest reported
- Last report date
- Oct 12, 2026
- EPS actual
- $4.73
- EPS estimate
- -$0.60
- Revenue actual
- $673.1M
- Revenue estimate
- $24.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +218.7%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $34
- PT range
- $32 – $36
- Analysts
- 7
7 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 12, 2026 | -$0.60 | $4.73 | Beat 887.14% | $673.1M |
| Jul 9, 2026 | -$0.73 | -$0.81 | Miss -10.96% | $9.0M |
| Apr 8, 2026 | -$0.76 | -$0.79 | Miss -3.95% | $6.3M |
| Jan 28, 2026 | -$0.84 | -$0.82 | Beat 2.38% | $13.6M |
| Oct 9, 2025 | -$0.84 | -$1.03 | Miss -22.62% | $7.9M |
| Jul 9, 2025 | -$0.71 | -$0.52 | Beat 26.76% | $44.1M |
| Apr 8, 2025 | -$0.72 | -$0.67 | Beat 6.94% | $18.5M |
| Jan 28, 2025 | -$0.67 | -$0.75 | Miss -11.94% | $13.3M |
| Oct 11, 2024 | -$0.67 | -$0.67 | In line | $12.6M |
| Jul 11, 2024 | -$0.66 | -$0.71 | Miss -7.58% | $12.1M |
| Apr 10, 2024 | -$0.80 | -$0.76 | Beat 5.00% | $16.6M |
| Feb 15, 2024 | -$0.51 | -$0.77 | Miss -50.98% | $15.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 17, 2027